Keyphrases
Duchenne muscular Dystrophy
100%
Spinal muscular Atrophy
33%
Ultrasound
26%
Quantitative Ultrasound
22%
Onasemnogene Abeparvovec
20%
Nerve
19%
Electrical Impedance Myography
19%
Gene Therapy
17%
Dystrophin
16%
Delandistrogene Moxeparvovec
16%
Backscatter
15%
Neuromuscular Disease
15%
Young children
14%
Phase II Trial
12%
Backscatter Analysis
12%
Ultrasound Examination
12%
Corticosteroids
12%
Intraclass Correlation Coefficient
10%
Skeletal muscle
10%
Quantitative muscle Ultrasound
10%
Grayscale Level
10%
Nusinersen
10%
Nerve Ultrasound
10%
Non-ambulatory
10%
Randomized Double-blind
9%
SMN2
9%
Viltolarsen
9%
Becker muscular Dystrophy
9%
Givinostat
9%
Placebo-controlled
9%
Muscle Thickness
9%
Disease Progression
9%
Muscular Dystrophy
9%
Adverse Events
8%
United States
8%
Myopathy
8%
Muscle Ultrasound
8%
Nerve Enlargement
8%
Clinical Trials
8%
Spinal muscular Atrophy Type 1
8%
Electrodiagnosis
7%
SMN2 Copies
7%
Chronic Inflammatory Demyelinating Polyneuropathy
7%
Placebo
7%
Pediatric
6%
PYROXD1
6%
Non-ambulatory Patients
6%
Phenotypic Spectrum
6%
Nerve Transfer
6%
Polyneuropathy
6%
Medicine and Dentistry
Duchenne Muscular Dystrophy
91%
Spinal Muscular Atrophy
23%
Myography
19%
Ultrasonography of Muscle
17%
Onasemnogene Abeparvovec
17%
Skeletal Muscle
16%
Gene Therapy
16%
Dystrophin
15%
Adverse Event
14%
Placebo
11%
Upper Limb
11%
Electrodiagnosis
11%
Myopathy
11%
Muscle Disease
10%
Arm
10%
Viltolarsen
9%
Becker Muscular Dystrophy
9%
Givinostat
9%
Limb
9%
Disease Exacerbation
8%
Echography
8%
Clinical Trial
8%
Werdnig Hoffmann Disease
8%
Exon
7%
Neuromuscular Disease
7%
Neuropathy
7%
Combination Therapy
7%
Magnetic Resonance Imaging
6%
Pediatrics
6%
Diseases
6%
Nerve Transplantation
6%
Chronic Inflammatory Demyelinating Polyneuropathy
6%
Blood Flow
6%
Polyneuropathy
6%
Bayley Scales of Infant Development
5%
Median Nerve
5%
Spinal Cord Injury
5%
Peripheral Nerve
5%
